Latest News
Merck KGaA
- Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
- Moderna, Merck Shares Fall After Possible Melanoma Data Leak
- ESMO: After leak, Merck and Moderna post phase 3 cancer vaccine data early
- Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
- Merck KGaA bets on RNAi with $1.3B Silence buyout
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Watch CNBC's full interview with Merck CEO Rob Davis
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potential
- Merck's experimental skin disease drug succeeds in mid-stage study
- Merck pulls antibiotic for multidrug-resistant infections from US market
- Merck's drug for diabetes-related eye disease meets trial goal
Headlines from the last 30 days, linking to the original publishers. See all market news →